Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvaro Moreno

Showing results (101-110 of 129) with videos related to

Pageof 13
Sort By:
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
Frontiers in Immunology|February 16, 2026
Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapyAndrew Liu, Brian Necela, Zhuo Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527Rachel A Freedman, Jared C Foster, Drew K Seisler, et al.
Cancer|October 19, 2018
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.
Breast Cancer Research : BCR|May 24, 2023
Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumorsXiaojia Tang, Kevin J Thompson, Krishna R Kalari, et al.
British Journal of Cancer|September 1, 2022
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO studyGuilherme Nader-Marta, Véronique Debien, Daniel Eiger, et al.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
Journal of Asthma and Allergy|April 9, 2026
Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort StudyAna Montoro Ferrer, María Del Mar Moro Moro, Fernando Miguel Parra Borreguero, et al.
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trialChris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Pageof 13

Showing results (101-110 of 129) with videos related to

Sort By:
Pageof 13
Breast Cancer Research and Treatment|May 29, 2019
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trialMatteo Lambertini, Christine Campbell, Richard D Gelber, et al.
Frontiers in Immunology|February 16, 2026
Long-term cellular and humoral responses to SARS-CoV-2 vaccinations in patients with solid malignancies undergoing chemotherapyAndrew Liu, Brian Necela, Zhuo Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2016
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527Rachel A Freedman, Jared C Foster, Drew K Seisler, et al.
Cancer|October 19, 2018
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trialsMatteo Lambertini, Samuel Martel, Christine Campbell, et al.
Breast Cancer Research : BCR|May 24, 2023
Integration of multiomics data shows down regulation of mismatch repair and tubulin pathways in triple-negative chemotherapy-resistant breast tumorsXiaojia Tang, Kevin J Thompson, Krishna R Kalari, et al.
British Journal of Cancer|September 1, 2022
Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO studyGuilherme Nader-Marta, Véronique Debien, Daniel Eiger, et al.
NPJ Breast Cancer|July 20, 2022
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancerElisa Agostinetto, Lieveke Ameye, Samuel Martel, et al.
Journal of Asthma and Allergy|April 9, 2026
Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort StudyAna Montoro Ferrer, María Del Mar Moro Moro, Fernando Miguel Parra Borreguero, et al.
The Lancet. Oncology|October 21, 2015
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trialEdith A Perez, Ahmad Awada, Joyce O'Shaughnessy, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2017
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trialChris Twelves, Javier Cortés, Joyce O'Shaughnessy, et al.
Pageof 13